Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any colorectal cancer in which the cause of the disease is a mutation in the SMAD7 gene.
Features include: Colon cancer.
Biomarker and diagnostic research for colorectal cancer, susceptibility to, 3 has been reported in the published literature.
No clinical trials have been registered for colorectal cancer, susceptibility to, 3.
251 publications have been identified in PubMed for colorectal cancer, susceptibility to, 3. Research spans Epidemiology / Natural History (35%), Basic Science / Preclinical (31%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 89 | 35% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
Online Mendelian Inheritance in Man
Common questions about colorectal cancer, susceptibility to, 3
Laboratory research
79 |
31% |
Research summaries | 45 | 18% |
Testing and diagnosis research | 16 | 6% |
Clinical study results | 10 | 4% |
Patient case studies | 6 | 2% |
New treatment approaches | 5 | 2% |
Other research | 1 | 0% |
Guo Z (2026). [PMID: 41240371](https://pubmed.ncbi.nlm.nih.gov/41240371/). *The British journal of dermatology*. [Basic Science / Preclinical]
Zhou Y (2026). [PMID: 41272180](https://pubmed.ncbi.nlm.nih.gov/41272180/). *Archives of toxicology*. [Epidemiology / Natural History]
Sommer AK (2026). [PMID: 41524686](https://pubmed.ncbi.nlm.nih.gov/41524686/). *Gastroenterology*. [Diagnostic / Biomarker]
Lu L (2026). [PMID: 42204638](https://pubmed.ncbi.nlm.nih.gov/42204638/). *Cancer Med*. [Basic Science / Preclinical]
Fryer E (2026). [PMID: 41085561](https://pubmed.ncbi.nlm.nih.gov/41085561/). *Cancer Epidemiol Biomarkers Prev*. [Epidemiology / Natural History]
Sanchez Mendez J (2026). [PMID: 41920173](https://pubmed.ncbi.nlm.nih.gov/41920173/). *Cancer Epidemiol Biomarkers Prev*. [Diagnostic / Biomarker]
Öztürk Hİ (2026). [PMID: 41870855](https://pubmed.ncbi.nlm.nih.gov/41870855/). *Probiotics Antimicrob Proteins*. [Basic Science / Preclinical]
Djaballah-Ider FZ (2026). [PMID: 42123295](https://pubmed.ncbi.nlm.nih.gov/42123295/). *Int J Mol Sci*. [Clinical Trial Publication]
Zhu F (2026). [PMID: 42113310](https://pubmed.ncbi.nlm.nih.gov/42113310/). *Inflamm Res*. [Basic Science / Preclinical]
Frascatani R (2026). [PMID: 42073556](https://pubmed.ncbi.nlm.nih.gov/42073556/). *Cancers (Basel)*. [Review / Meta-Analysis]
AI-curated news mentioning colorectal cancer, susceptibility to, 3
Updated Apr 15, 2010
A CDC study reveals that over 75% of primary care physicians prefer in-office fecal occult blood tests for colorectal cancer screening, despite home-based tests being more accurate. This highlights a significant gap in screening practices that could impact early detection efforts.